Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.

作者: Jitender Sareen , Alla Kirshner , Mark Lander , Kevin D. Kjernisted , Michael K. Eleff

DOI: 10.1016/J.JAD.2004.03.011

关键词: PsychologySerotonin reuptake inhibitorAnxiety disorderPsychiatryAntipsychoticOlanzapineAtypical antipsychoticRisperidoneAntidepressantQuetiapine

摘要: Abstract Background: Paradoxically, some reports in the literature support use of antipsychotics treatment Obsessive Compulsive Disorder (OCD), while other suggest that can exacerbate OCD symptoms. To date, there is no published systematic review relationship between symptoms and antipsychotic drugs. Methods: A Medline PsychInfo search (1980–2003) was conducted to collect interactions Results: In refractory OCD, case series, open label trials placebo-controlled were found suggesting efficacy augmentation ongoing antidepressant treatment. with haloperidol, risperidone, olanzapine, quetiapine, a significantly higher response rate (46–71%) for groups, compared placebo groups. Reports exacerbation atypical limited individuals primary psychotic disorder. Limitations: Definition most these studies based on modest reduction symptoms, available long-term efficacy. There also systematically evaluated incidence associated antipsychotics. Conclusions: All mentioned above had short-term controlled evidence their as augmenting agents OCD. The suggested management induction/exacerbation due increase dose and/or add selective serotonin reuptake inhibitor.

参考文章(45)
Baker Rw, Umbricht Ds, Ames D, Schooler Nr, Chengappa Kn, OBSESSIVE-COMPULSIVE SYMPTOMS IN SCHIZOPHRENIA : A COMPARISON OF OLANZAPINE AND PLACEBO Psychopharmacology Bulletin. ,vol. 32, pp. 89- 93 ,(1996)
Lisa Calvocoressi, Barbara Lewis, Mary Harris, Sally J Trufan, Wayne K Goodman, Christopher J McDougle, Lawrence H Price, Family accommodation in obsessive-compulsive disorder. American Journal of Psychiatry. ,vol. 152, pp. 441- 443 ,(1995) , 10.1176/AJP.152.3.441
L Warneke, P Tibbo, Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap. Journal of Psychiatry & Neuroscience. ,vol. 24, pp. 15- 24 ,(1999)
Michael A. Jenike, Scott L. Rauch, Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. The Journal of Clinical Psychiatry. ,vol. 55, pp. 11- 17 ,(1994)
Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder American Journal of Psychiatry. ,vol. 147, pp. 652- 654 ,(1990) , 10.1176/AJP.147.5.652
L Ravizza, F Bogetto, S Bellino, G Maina, G Barzega, Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacology Bulletin. ,vol. 32, pp. 677- 682 ,(1996)
Saxena S, Baxter Lr, Bystritsky A, Wang D, Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. The Journal of Clinical Psychiatry. ,vol. 57, pp. 303- 306 ,(1996)
Steven A. Rasmussen, Jane L. Eisen, The epidemiology and differential diagnosis of obsessive compulsive disorder. The Journal of Clinical Psychiatry. ,vol. 53, pp. 4- 6 ,(1992) , 10.1007/978-3-642-77608-3_1
Stefano Pallanti, Donatella Marazziti, Carol A Bienstock, Benjamin D Greenberg, Sanjaya Saxena, Steven A Rasmussen, Eric Hollander, Lorrin M Koran, Joseph Zohar, Yehuda Sasson, Luigi Ravizza, Chawkie Benkelfat, Refractory obsessive-compulsive disorder: state-of-the-art treatment The Journal of Clinical Psychiatry. ,vol. 63, pp. 20- 29 ,(2002)